ASCO 2020

Por Bartsch, Rupert, Dieras, Veronique, Cortes, Javier, Müller, Volkmar, Ruhstaller, Thomas
Publicado no Breast Care (Basel) (2020)

Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8–11, 2020

Por Müller, Volkmar, Dieras, Veronique, Cardoso, Fatima, Cameron, David, Cortes, Javier
Publicado no Breast Care (Basel) (2021)

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic H...

Por Paracha, Noman, Reyes, Adriana, Diéras, Véronique, Krop, Ian, Pivot, Xavier, Urruticoechea, Ander
Publicado no Breast Cancer Res Treat (2020)

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib

Por Zheng, Jenny, Yu, Yanke, Durairaj, Chandrasekar, Diéras, Véronique, Finn, Richard S., Wang, Diane D.
Publicado no Target Oncol (2020)

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall...

Por Diéras, Véronique, Miles, David, Verma, Sunil, Pegram, Mark, Welslau, Manfred, Baselga, José, Krop, Ian E, Blackwell, Kim, Hoersch, Silke, Xu, Jin, Green, Marjorie, Gianni, Luca
Publicado no Lancet Oncol (2017)

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer

Por Bernadou, Guillemette, Campone, Mario, Merlin, Jean‐Louis, Gouilleux‐Gruart, Valérie, Bachelot, Thomas, Lokiec, François, Rezai, Keyvan, Arnedos, Monica, Diéras, Véronique, Jimenez, Marta, Paintaud, Gilles, Ternant, David
Publicado no Br J Clin Pharmacol (2016)

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

Por Diéras, Véronique, Harbeck, Nadia, Joy, Anil Abraham, Gelmon, Karen, Ettl, Johannes, Verma, Sunil, Lu, Dongrui R., Gauthier, Eric, Schnell, Patrick, Mori, Ave, Rugo, Hope S., Finn, Richard S.
Publicado no Oncologist (2019)

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

Por Wilson, Richard H, Evans, TR Jeffry, Middleton, Mark R, Molife, L Rhoda, Spicer, James, Dieras, Veronique, Roxburgh, Patricia, Giordano, Heidi, Jaw-Tsai, Sarah, Goble, Sandra, Plummer, Ruth
Publicado no Br J Cancer (2017)

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated...

Por Sabatier, Renaud, Diéras, Véronique, Pivot, Xavier, Brain, Etienne, Roché, Henri, Extra, Jean-Marc, Monneur, Audrey, Provansal, Magali, Tarpin, Carole, Bertucci, François, Viens, Patrice, Zemmour, Christophe, Gonçalves, Anthony
Publicado no Cancer Res Treat (2018)

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

Por Tripathy, Debu, Tolaney, Sara M, Seidman, Andrew D, Anders, Carey K, Ibrahim, Nuhad, Rugo, Hope S, Twelves, Chris, Dieras, Veronique, Müller, Volkmar, Tagliaferri, Mary, Hannah, Alison L, Cortés, Javier
Publicado no Future Oncol (2019)

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

Por Diéras, Véronique, Bachelot, Thomas, Campone, Mario, Isambert, Nicolas, Joly, Florence, Le Tourneau, Christophe, Cassier, Philippe, Bompas, Emmanuelle, Fumoleau, Pierre, Noal, Sabine, Orsini, Christine, Jimenez, Marta, Imbs, Diane Charlotte, Chatelut, Etienne
Publicado no Oncol Ther (2016)

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

Por Reyal, Fabien, Bollet, Marc A., Caly, Martial, Gentien, David, Carpentier, Sabrina, Peyro-Saint-Paul, Hélène, Pierga, Jean-Yves, Cottu, Paul, Dieras, Véronique, Sigal-Zafrani, Brigitte, Vincent-Salomon, Anne, Sastre-Garau, Xavier
Publicado em 2012

Correction: Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

Por Reyal, Fabien, Bollet, Marc A., Caly, Martial, Gentien, David, Carpentier, Sabrina, Peyro-Saint-Paul, Hélène, Pierga, Jean-Yves, Cottu, Paul, Dieras, Véronique, Sigal-Zafrani, Brigitte, Vincent-Salomon, Anne, Sastre-Garau, Xavier
Publicado em 2012

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Por Verma, Sunil, Miles, David, Gianni, Luca, Krop, Ian E., Welslau, Manfred, Baselga, José, Pegram, Mark, Oh, Do-Youn, Diéras, Véronique, Guardino, Ellie, Fang, Liang, Lu, Michael W., Olsen, Steven, Blackwell, Kim
Publicado no N Engl J Med (2012)

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients

Por Jobard, Elodie, Trédan, Olivier, Bachelot, Thomas, Vigneron, Arnaud M., Aït-Oukhatar, Céline Mahier, Arnedos, Monica, Rios, Maria, Bonneterre, Jacques, Diéras, Véronique, Jimenez, Marta, Merlin, Jean-Louis, Campone, Mario, Elena-Herrmann, Bénédicte
Publicado no Oncotarget (2017)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer

Por Diéras, Véronique, Rugo, Hope S, Schnell, Patrick, Gelmon, Karen, Cristofanilli, Massimo, Loi, Sherene, Colleoni, Marco, Lu, Dongrui R, Mori, Ave, Gauthier, Eric, Huang Bartlett, Cynthia, Slamon, Dennis J, Turner, Nicholas C, Finn, Richard S
Publicado no J Natl Cancer Inst (2018)

MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer

Por Dickler, Maura N., Tolaney, Sara M., Rugo, Hope S., Cortés, Javier, Diéras, Véronique, Patt, Debra, Wildiers, Hans, Hudis, Clifford A., O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Frenzel, Martin, Koustenis, Andrew, Baselga, José
Publicado no Clin Cancer Res (2017)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

Por Hatem, Rana, Botty, Rania El, Chateau-Joubert, Sophie, Servely, Jean-Luc, Labiod, Dalila, de Plater, Ludmilla, Assayag, Franck, Coussy, Florence, Callens, Céline, Vacher, Sophie, Reyal, Fabien, Cosulich, Sabina, Diéras, Véronique, Bièche, Ivan, Marangoni, Elisabetta
Publicado no Oncotarget (2016)

NT-23 PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)

Por Kerklaan, Bojana Milojkovic, Jager, Agnes, Aftimos, Philippe, Dieras, Veronique, Altintas, Sevilay, Anders, Carey, Arnedos, Monica, Gelderblom, Hans, Soetekouw, Patricia, Gladdines, Werner, Gaillard, Pieter, de Sousa, Carlos, Awada, Ahmad, Schellens, Jan, van Linde, Myra, Brandsma, Dieta
Publicado em 2014

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rati...

Por Isakoff, Steven J, Puhalla, Shannon, Domchek, Susan M, Friedlander, Michael, Kaufman, Bella, Robson, Mark, Telli, Melinda L, Diéras, Véronique, Han, Hyo Sook, Garber, Judy E, Johnson, Eric F, Maag, David, Qin, Qin, Giranda, Vincent L, Shepherd, Stacie P
Publicado no Future Oncol (2017)